Altre lingue Race Oncology Limited

Azioni

Mercato chiuso - Australian S.E. Altri mercati azionari 08:10:56 28/05/2024			Variaz. 5gg	Var. 1 gen.
1,405 ^AUD	-3,77%		-5,70%	+67,26%

26/03	Race Oncology ottiene il certificato di analisi per RC220; le azioni salgono di quasi il 6%.	MT
06/03	Race Oncology dice che lo studio mostra l'efficacia della sua attività principale nel trattamento del cancro del sangue	MT

Race Oncology's breakthrough in cancer cell treatment	15/05
Race Oncology Obtains Certificate of Analysis for RC220; Shares Up Almost 6%	26/03
Race Oncology Limited(ASX:RAC) dropped from S&P/ASX All Ordinaries Index	18/03
Race Oncology Says Study Shows Lead Asset's Efficacy in Blood Cancer Treatment	06/03
Race Oncology looks to accelerate clinical development of bisantrene	28/02
Race Oncology Widens Loss in Fiscal H1	28/02
Race Oncology Limited Reports Earnings Results for the Half Year Ended December 31, 2023	27/02
Race Oncology appoints Dr Daniel Tillett as CEO	23/11
Race Oncology Names CEO; Shares Jump 5%	22/11
Race Oncology Limited Appoints Daniel Tillett as Chief Executive Officer	21/11
Race Oncology highlights impressive bisantrene clinical data	07/11
Race Oncology kicks off safety studies for RC220	09/10/23
Race Oncology Initiates Toxicology, Safety Pharmacology Studies of Chemotherapy Drug	05/10/23
Race Oncology Limited(ASX:RAC) dropped from S&P Global BMI Index	18/09/23
Race Oncology Limited Reports Earnings Results for the Full Year Ended June 30, 2023	30/08/23
Race Oncology Limited Announces Board Changes	22/08/23
Race Oncology at the heart of cancer care	09/08/23
Race Oncology announces deal with manufacturer Ardena to develop companyÃ¢€™s new IV formulation RC220	19/07/23
Race Oncology Secures More R&D Tax Rebate for Fiscal Year 2022; Shares Rise 4%	13/07/23
Race Executes Agreement with Ardena for GMP Manufacturing of RC220	12/07/23

Non ci sono risultati per questa ricerca